Patricia Ostler

1.1k total citations
16 papers, 883 citations indexed

About

Patricia Ostler is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Patricia Ostler has authored 16 papers receiving a total of 883 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Patricia Ostler's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (6 papers). Patricia Ostler is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (7 papers) and Lung Cancer Research Studies (6 papers). Patricia Ostler collaborates with scholars based in United States. Patricia Ostler's co-authors include Thomas J. Lynch, Joan Lucca, Bruce E. Johnson, Pasi A. Jänne, Arthur T. Skarin, Beow Y. Yeap, Jennifer S. Temel, Panos Fidias, Panos Fidias and David M. Jackman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Thoracic Oncology.

In The Last Decade

Patricia Ostler

16 papers receiving 849 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patricia Ostler United States	10	621	619	174	126	102	16	883
Philippe Rochigneux France	14	406 0.7×	132 0.2×	140 0.8×	93 0.7×	97 1.0×	39	649
F. Figoli Italy	10	363 0.6×	336 0.5×	62 0.4×	32 0.3×	143 1.4×	29	554
Stephen Begbie Australia	7	702 1.1×	789 1.3×	63 0.4×	32 0.3×	146 1.4×	23	1.1k
Patra Grevstad United States	6	803 1.3×	821 1.3×	36 0.2×	43 0.3×	202 2.0×	10	1.1k
C.M. Woodroffe United Kingdom	10	457 0.7×	458 0.7×	50 0.3×	45 0.4×	140 1.4×	14	711
Carmel Pezaro Australia	8	233 0.4×	200 0.3×	112 0.6×	98 0.8×	114 1.1×	15	459
Francovito Piantedosi Italy	7	507 0.8×	472 0.8×	73 0.4×	32 0.3×	42 0.4×	12	774
Christelle Clément-Duchêne France	15	379 0.6×	391 0.6×	65 0.4×	28 0.2×	196 1.9×	53	804
Ray Snyder Australia	10	652 1.0×	170 0.3×	81 0.5×	80 0.6×	144 1.4×	14	843
N.J. Latino Israel	10	295 0.5×	185 0.3×	90 0.5×	59 0.5×	29 0.3×	17	654

Countries citing papers authored by Patricia Ostler

Since Specialization

Citations

This map shows the geographic impact of Patricia Ostler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Ostler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Ostler more than expected).

Fields of papers citing papers by Patricia Ostler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Ostler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Ostler. The network helps show where Patricia Ostler may publish in the future.

Co-authorship network of co-authors of Patricia Ostler

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Ostler. A scholar is included among the top collaborators of Patricia Ostler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Ostler. Patricia Ostler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Sequist, Lecia V., Panos Fidias, Rebecca S. Heist, et al.. (2009). Brief Report of Biweekly Pemetrexed and Gemcitabine in Elderly Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(9). 1170–1173. 1 indexed citations

Jackman, David M., Hedy L. Kindler, Beow Y. Yeap, et al.. (2008). Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 113(4). 808–814. 85 indexed citations

Temel, Jennifer S., Jessica B. McCannon, Joseph A. Greer, et al.. (2008). Aggressiveness of care in a prospective cohort of patients with advanced NSCLC. Cancer. 113(4). 826–833. 86 indexed citations

Temel, Jennifer S., Vicki A. Jackson, J. Andrew Billings, et al.. (2007). Phase II Study: Integrated Palliative Care in Newly Diagnosed Advanced Non–Small-Cell Lung Cancer Patients. Journal of Clinical Oncology. 25(17). 2377–2382. 115 indexed citations

Jackman, David M., Beow Y. Yeap, Neal I. Lindeman, et al.. (2007). Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(7). 760–766. 254 indexed citations

Jackman, D. M., B.Y. Yeap, Joan Lucca, et al.. (2006). Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response. Journal of Clinical Oncology. 24(18_suppl). 7168–7168. 4 indexed citations

Jackman, D. M., Joan Lucca, P. Fidias, et al.. (2005). Phase II study of the EGFR tyrosine kinase erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma. Journal of Clinical Oncology. 23(16_suppl). 7148–7148. 15 indexed citations

Sequist, Lecia V., P. Fidias, Jennifer S. Temel, et al.. (2005). Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 7275–7275. 2 indexed citations

Jackman, D. M., Joan Lucca, P. Fidias, et al.. (2005). O-188 Phase II study of the EGFR tyrosine kinase inhibitor erlotinib (Tarceva) in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma. Lung Cancer. 49. S62–S63. 2 indexed citations

10.

Fidias, Panos, Jennifer S. Temel, Elizabeth A. Kennedy, et al.. (2005). P-572 Phase I–II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel(P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Lung Cancer. 49. S268–S269. 1 indexed citations

11.

Jänne, Pasi A., Sarada Gurubhagavatula, Beow Y. Yeap, et al.. (2004). Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study. Lung Cancer. 44(2). 221–230. 169 indexed citations

12.

Lucca, Joan, Michael S. Rabin, Thomas J. Lynch, et al.. (2004). Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. Journal of Clinical Oncology. 22(14_suppl). 7080–7080. 7 indexed citations

13.

Johnson, Bruce E., Joan Lucca, Michael S. Rabin, et al.. (2004). Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma. Journal of Clinical Oncology. 22(14_suppl). 7080–7080. 25 indexed citations

14.

Wirth, Lori J., Joan Lucca, Patricia Ostler, et al.. (2003). Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.. PubMed. 9(5). 1698–704. 10 indexed citations

15.

Jänne, Pasi A., Sarada Gurubhagavatula, Joan Lucca, et al.. (2003). O-243 Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib (“Iressa”, ZD1839) in the compassionate use program. Lung Cancer. 41. S71–S71. 12 indexed citations

16.

Fidias, Panos, Jeffrey G. Supko, Anthony Boral, et al.. (2001). A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.. PubMed. 7(12). 3942–9. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact